Articles by Sanjay Garg, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Sanjay Garg, PhD

Biopharmaceutical Form and Function

A timely new book explains techniques for conformational analysis.
Jun 2, 2010

A timely new book explains techniques for conformational analysis.

Quality in, Quality Out

A book guides readers through the regulatory requirements for computerized quality systems.
Jun 2, 2009

A book guides readers through the regulatory requirements for computerized quality systems.

A Peak in Mass-Spectrometry Literature

A book about pharmaceutical analysis engages the reader with history and unexpected asides.
Dec 2, 2008

A book about pharmaceutical analysis engages the reader with history and unexpected asides.

Charting a Path to Purity

Regulators and industry professionals provide a guide for identifying and measuring impurities.
Oct 2, 2007

Regulators and industry professionals provide a guide for identifying and measuring impurities.

An Update on Osmotic Drug Delivery

Aug 2, 2003

The authors review patent literature that describes new developments in osmotic drug delivery such as pulsatile, delayed, and volume amplifier delivery devices.

Current Status of Drug Delivery Technologies and Future Directions

Feb 2, 2001

Evolution of an existing drug molecule from a conventional form to a novel delivery system can significantly improve its performance in terms of patient compliance, safety, and efficacy. These days,drug delivery companies are engaged in the development of multiple platform technologies to get competitive advantage, extend patent life, and increase market share of their products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here